Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors

Int J Hematol. 2021 Nov;114(5):572-579. doi: 10.1007/s12185-020-02951-5. Epub 2020 Jul 23.

Abstract

The use of allogeneic, pluripotent stem cell-derived immune cells for cancer immunotherapy has been the subject of recent research, including clinical trials. The use of pluripotent stem cells as the source for allogeneic immune cells facilitates stringent quality control of the final product, regarding efficacy, safety, and producibility. In this review, we have described the characteristics of natural killer (NK) cells from multiple cell sources, including pluripotent stem cells, the chimeric antigen receptor (CAR)-modification method and strategy for these NK cells, and the current and planned clinical trials of CAR-modified induced pluripotent stem cell-derived NK cells.

Keywords: Chimeric antigen receptor; Immunotherapy; Induced pluripotent stem cell; Natural killer cell.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigens, Neoplasm / immunology
  • Clinical Studies as Topic
  • Combined Modality Therapy
  • Drug Evaluation, Preclinical
  • Gene Expression*
  • Genetic Engineering
  • Humans
  • Immunotherapy, Adoptive* / adverse effects
  • Immunotherapy, Adoptive* / methods
  • Induced Pluripotent Stem Cells / cytology*
  • Induced Pluripotent Stem Cells / metabolism
  • Killer Cells, Natural / cytology
  • Killer Cells, Natural / immunology*
  • Killer Cells, Natural / metabolism*
  • Neoplasms / etiology
  • Neoplasms / therapy*
  • Prognosis
  • Receptors, Chimeric Antigen / genetics*
  • Receptors, Chimeric Antigen / immunology
  • Treatment Outcome

Substances

  • Antigens, Neoplasm
  • Receptors, Chimeric Antigen